Does the FDA label list hair loss as a side effect of Wegovy?

Yes. In Table 3 of the Wegovy prescribing information (adults with obesity or overweight), hair loss was reported in 3% of Wegovy 2.4 mg patients versus 1% on placebo. In the pediatric table (ages 12 and older), it was 4% versus 0%.

What does the Zepbound label say about hair loss?

Hair loss is listed among the most common adverse reactions (5% or more). The label states that hair loss in treated patients 'was associated with weight reduction,' and reports it more often in women (7.1%) than men (0.5%) in a pool of two studies. No Zepbound-treated patients stopped treatment because of it.

Is hair loss on a GLP-1 permanent?

The labels we reviewed do not say whether hair regrows or how long it lasts, so we cannot state that. This is a question for your prescriber or a dermatologist.

Does the label say the drug itself damages hair?

No. The Zepbound label ties hair loss to weight reduction rather than naming a direct effect of the drug. The Wegovy label reports the rate without explaining a cause. Neither label gives a mechanism we can cite.

Do these numbers apply to compounded semaglutide or tirzepatide?

No. The figures come from clinical trials of the FDA-approved products. Compounded versions are not FDA-approved and have no comparable labeling, so these rates cannot be assumed to apply.

GLP-1 and Hair Loss: What the Wegovy and Zepbound Labels Actually Report

How often hair loss appeared in the FDA-approved labeling for Wegovy and Zepbound, what the Zepbound label says about weight reduction and sex differences, and when to bring it up with your prescriber.

Hair shedding is one of the questions people ask weeks into a GLP-1 program, usually with some alarm. The answer is narrower than social media suggests: the approved labels report a rate, and in one case a qualifier, and say little else.

What the Wegovy label reports

The prescribing information for Wegovy (semaglutide) lists hair loss in its adverse-reactions tables. Among adults with obesity or overweight, 3% of patients on Wegovy 2.4 mg reported hair loss versus 1% on placebo (Table 3, which covers reactions at 2% or more and more frequent than placebo). In the table for pediatric patients 12 and older, it was 4% versus 0% (Table 4), in a much smaller trial of 133 treated patients.

Those are rates from controlled trials. They tell you hair loss was reported more often on the drug than on placebo; they do not tell you how long it lasted or whether it resolved, and the sections we read do not either.

What the Zepbound label reports

Zepbound (tirzepatide) goes further. Hair loss is on the list of most common adverse reactions, reported in 5% or more of treated patients. In the dose table, it ranged from 4% to 5% across the 5, 10 and 15 mg groups, against 1% on placebo.

The label also has a dedicated hair-loss paragraph. It says hair loss “was associated with weight reduction.” In a pool of two studies it was reported more often in women than men: 7.1% of women versus 0.5% of men on Zepbound, and 1.3% versus 0% on placebo. It adds that no Zepbound-treated patients, and one placebo patient, stopped treatment because of hair loss.

What the labels do not say

Neither label we read states how long hair loss lasts or whether hair regrows.
Neither gives a mechanism we can cite. Zepbound’s wording links it to weight reduction, not to a direct effect on the hair follicle; we will not go beyond that.
Neither offers a treatment recommendation. Anyone selling a supplement as the “FDA-backed fix” is overstating what exists.

Why compounded products complicate this

All of the figures above are from trials of FDA-approved products. Compounded semaglutide and tirzepatide are not FDA-approved, and there is no equivalent labeling for them. If you are on a compounded product, you cannot assume these rates apply. Our guide on brand vs. compounded GLP-1 explains the legal distinction, and how to verify your clinic’s prescriber and pharmacy covers what to check.

When to raise it with your prescriber

Any new or worsening symptom is worth mentioning at a follow-up, and hair loss is no exception, especially if it is sudden, patchy, or comes with other changes. The label wording is population-level data, not an assessment of your hair. A prescriber who knows your history can decide whether to look at other causes such as thyroid function or nutrition. This is general information, not medical advice.

That is the practical reason we list only clinics with a named, NPI-verified prescriber: follow-up questions need someone reachable. Browse the verified Houston clinics and read our methodology. For eating during dose week, see the post-dose week FAQ.

Sources: U.S. National Library of Medicine, DailyMed, “WEGOVY- semaglutide injection, solution” (Section 6.1, Tables 3 and 4), retrieved October 14, 2026. DailyMed, “ZEPBOUND- tirzepatide injection, solution” (Highlights, Section 6.1 and Medication Guide; label revised 8/2026), retrieved October 14, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.